Compare Dyne Therapeutics Inc. Common Stock (DYN) vs EchoStar Corporation Common Stock (ECHO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs EchoStar Corporation Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while EchoStar Corporation Common Stock trades at $87.13 (market cap $26.63B). The key difference: EchoStar Corporation Common Stock is far larger — about 9.3× Dyne Therapeutics Inc. Common Stock's market cap, and EchoStar Corporation Common Stock is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and EchoStar Corporation Common Stock for 6 Days on average.
| DYN | ECHO | |
|---|---|---|
Market Cap | $2.86B | $26.63B |
Volume | 3,341,579 | 2,918,300 |
Sector | Health | Media |
52-Week High | $26.78 | $141.80 |
52-Week Low | $14.60 | $66.93 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $43.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ECHO trades at $91.56, down 3.72% over 24 hours, with a neutral technical signal and mixed earnings history including a significant Q2 2026 beat. The company reported a net loss of $14.50 billion in 2025, with negative cash flows, though revenue remains substantial at $15.00 billion. Recent news highlights institutional investments and a strategic partnership with United Airlines for in-flight streaming.
Analyst consensus is strongly bullish with a $134.00 price target, but high risks stem from persistent losses, negative cash flow, and the Hughes unit's bankruptcy. The stock's appeal hinges on turnaround execution and debt reduction efforts outweighing fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About EchoStar Corporation Common Stock
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →
